Keep updated on our activities.
Discover our latest news and scrientific support

New tools for cell-based assays

Cell-based assays provide information about viability, proliferation, cytotoxicity, senescence, and death of a cell. These assays rely on reporter gene assays, which have a high sensitivity due to signal amplification of cell-signaling cascades and are therefore suitable for analysis of cell-signaling cascades. Cell-based assays are commonly used in high-throughput screening (HTS) formats. In order to discover better and safer pharmaceuticals, various public and private entities have increased their funding for R&D. Furthermore, advances in cell-based assay technologies have allowed researchers to use this method for drug discovery and toxicology studies.

Cell-based assays market growth is attributed to factors such as growing demand for cell-based assays in drug discovery, increased funding for cell-based research, and increasing number of companies engaged in drug discovery. Today, these companies seek new tools for cell-based applications in drug discovery and technological advancements in cell-based assays techniques to streamline workflow and empower data output as well as reduce costs and time.

Another important factor that drives market expansion is trying to reduce the animal tested by using living single cells allowing them to work closer to in vivo conditions.

Novel and disruptive technologies such as SPAchip® allows to monitor living single cell assays over long periods, offering new possibilities into high-throughput screening methodologies and improving the R&D opportunities by increasing the usage of cell-based assay techniques for toxicity studies, drug screening, in-vitro testing, and others.

CytoCHECK SPAchip® detection kits combine the advantages of traditional cell-based assays with most advanced upgrades allowing researchers to identify problems with lead compounds earlier in the drug discovery process, resulting in enhanced efficiency and time-cost effective achieving to accelerate drug development options.


European Union